Fast-food chain McDonald’s, an economic indicator because of its mammoth global presence, posted its worst earnings report since 2020.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
AI-powered search engine startup Perplexity announced a revenue-sharing program on Tuesday with a handful of media companies.
Suppliers are upset Temu is swapping to a more Amazon-esque supplier model and trying to drive prices ever-downward.
Vitol Group, the world’s largest independent oil trader, has paid around a record $6.4 billion in share buybacks to its employee-owners.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
A recent study adds more ammunition to the idea that disturbing the sea floor via deep sea mining could do serious ecological damage.
Pioneering online education company 2U filed for bankruptcy, even as the public writ large has gradually embraced online learning.
Taylor Swift may be signed to the label, but Universal Music Group somehow can’t find a way to make its business work.
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.
Pfizer, Moderna, and GlaxoSmithKline are developing vaccines for RSV to fill the gap on their balance sheets.
General Motors shares tumbled after the company said its driverless taxi division, Cruise, will suspend production of the Origin robotaxi.
Shell has started to shop around for buyers to offload its stake in an offshore wind project off the coast of Scotland.
To prepare for a slowdown of global trade, US retailers spent months building a massive inventory to prevent empty shelves.
Hertz’s recent track record leaves much to be desired: the rental-car company lost nearly $2.9 billion last year.
Investor worries about a fresh batch of US tariffs have dragged LVMH shares in Paris down 23.6% so far this year.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.